From glutamatergic dysfunction to cognitive impairment: Boundaries in the therapeutic of the schizophrenia

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1543-1548

  Gaspar, P A ^a,c   Bustamante, M L ^a,d   Rojo, L E ^b   Martinez, A ^c  

^a UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSIDAD ARTURO PRAT   (Chile)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Astrocytes; Cognitive deficits (CDs); Glutamatergic hypothesis; Glycine trasporters; Kynurenic acid (KYNA); Metabotropic glutamate receptors (mGluRs); N methyl D aspartate receptor (NMDAR); Schizophrenia treatment

Indexed keywords

GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER 1; IONOTROPIC RECEPTOR; KYNURENIC ACID; METABOTROPIC RECEPTOR;

ARTICLE; COGNITIVE DEFECT; GLIA CELL; HUMAN; NEUROTRANSMISSION; SCHIZOPHRENIA;

COGNITION DISORDERS; GLUTAMIC ACID; HUMANS; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA;

EID: 84862610247     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784790     Document Type: Article

References (64)

1. Goldman-Rakic, P. S. Working memory dysfunction in schizophrenia, J. Neuropsychiatry Clin. Neurosci., 1994, 6, 348-357.
2. Hoff, A. L.; Svetina, C.; Shields, G.; Stewart, J.; DeLisi, L. E. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia, Schizophr. Res., 2005, 78, 27-34.
3. Bonner-Jackson, A.; Grossman, L. S.; Harrow, M.; Rosen, C. Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge, Compr. Psychiatry, 2010, 51, 471-479.
4. Lee, J.; Park, S. Working memory impairments in schizophrenia: a meta-analysis, J. Abnorm. Psychol., 2005, 114, 599-611.
5. Baddeley, A. Working memory, Science, 1992, 255, 556-559.
6. Shamsi, S.; Lau, A.; Lencz, T.; Burdick, K. E.; Derosse, P.; Brenner, R.; Lindenmayer, J. P.; Malhotra, A. K. Cognitive and symptomatic predictors of functional disability in schizophrenia, Schizophr. Res., 2010, 126(1/3), 257-264.
7. Simon, A. E.; Cattapan-Ludewig, K.; Zmilacher, S.; Arbach, D.; Gruber, K.; Dvorsky, D. N.; Roth, B.; Isler, E.; Zimmer, A.; Umbricht, D. Cognitive functioning in the schizophrenia prodrome, Schizophr. Bull., 2007, 33, 761-771.
8. Woodward, N. D.; Purdon, S. E.; Meltzer, H. Y.; Zald, D. H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia, Int. J. Neuropsychopharmacol., 2005, 8, 457-472.
9. Ford, J. M.; Krystal, J. H.; Mathalon, D. H. Neural synchrony in schizophrenia: from networks to new treatments, Schizophr. Bull., 2007, 33, 848-852.
10. Bernstein, H. G.; Steiner, J.; and Bogerts, B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy, Expert. Rev. Neurother., 2009, 9, 1059-1071.
11. Javitt, D. C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia, Hillside J. Clin. Psychiatry, 1987, 9, 12-35.
12. Kim, J. S.; Kornhuber, H. H.; Schmid-Burgk, W.; Holzmuller, B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia, Neurosci. Lett., 1980, 20, 379-382.
13. Krystal, J. H.; Karper, L. P.; Seibyl, J. P.; Freeman, G. K.; Delaney, R.; Bremner, J. D.; Heninger, G. R.; Bowers, M. B. Jr.; Charney, D. S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch. Gen Psychiatry, 1994, 51, 199-214.
14. Carlsson, M. L.; Carlsson, A.; and Nilsson, M. Schizophrenia: from dopamine to glutamate and back, Curr. Med. Chem., 2004, 11, 267-277.
15. Lisman, J. E.; Coyle, J. T.; Green, R. W.; Javitt, D. C.; Benes, F. M.; Heckers, S.; Grace, A. A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia, Trends Neurosci., 2008, 31, 234-242.
16. Medoff, D. R.; Holcomb, H. H.; Lahti, A. C.; Tamminga, C. A. Probing the human hippocampus using rCBF: contrasts in schizophrenia, Hippocampus 11, 2001, 543-550.
17. Rowland, L. M.; Astur, R. S.; Jung, R. E.; Bustillo, J. R.; Lauriello, J.; Yeo, R. A. Selective cognitive impairments associated with NMDA receptor blockade in humans, Neuropsychopharmacology, 2005, 30, 633-639.
18. Malhotra, A. K.; Adler, C. M.; Kennison, S. D.; Elman, I.; Pickar, D.; Breier, A. Clozapine blunts N-methyl-D-aspartate antagonistinduced psychosis: a study with ketamine, Biol. Psychiatry, 1997, 42, 664-668.
19. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia, Trends Pharmacol. Sci., 2009, 30, 25-31.
20. Mirnics, K.; Middleton, F. A.; Marquez, A.; Lewis, D. A.; Levitt, P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex, Neuron, 2000, 28, 53-67.
21. Frankle, W. G.; Lerma, J.; Laruelle, M. The synaptic hypothesis of schizophrenia, Neuron, 2003, 39, 205-216.
22. Gozzi, A.; Herdon, H.; Schwarz, A.; Bertani, S.; Crestan, V.; Turrini, G.; Bifone, A. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat, Psychopharmacology (Berl.), 2008, 201, 273-284.
23. van Elst, L. T.; Valerius, G.; Buchert, M.; Thiel, T.; Rusch, N.; Bubl, E.; Hennig, J.; Ebert, D.; Olbrich, H. M. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study, Biol Psychiatry, 2005, 58, 724-730.
24. Shirayama, Y.; Obata, T.; Matsuzawa, D.; Nonaka, H.; Kanazawa, Y.; Yoshitome, E.; Ikehira, H.; Hashimoto, K.; and Iyo, M. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study, Neuroimage, 2010, 49, 2783-2790.
25. Javitt, D. C. Glutamate and schizophrenia: phencyclidine, Nmethyl- D-aspartate receptors, and dopamine-glutamate interactions, Int. Rev. Neurobiol., 2007, 78, 69-108.
26. Lewis, D. A.; Hashimoto, T.; Volk, D. W. Cortical inhibitory neurons and schizophrenia, Nat. Rev. Neurosci., 2005, 6, 312-324.
27. Wilson, F. A.; O'Scalaidhe, S. P.; Goldman-Rakic, P. S. Functional synergism between putative gamma-aminobutyrate-containing neurons and pyramidal neurons in prefrontal cortex, Proc. Natl. Acad. Sci. U S A, 1994, 91, 4009-4013.
28. Rao, S. G.; Williams, G. V.; Goldman-Rakic, P. S. Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory, J. Neurosci., 2000, 20, 485-494.
29. Gonzalez-Burgos, G.; and Lewis, D. A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia, Schizophr. Bull., 2008, 34, 944-961.
30. Hashimoto, T.; Volk, D. W.; Eggan, S. M.; Mirnics, K.; Pierri, J. N.; Sun, Z.; Sampson, A. R., and Lewis, D. A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia, J. Neurosci., 2003, 23, 6315-6326.
31. Lewis, D. A.; Moghaddam, B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations, Arch. Neurol., 2006, 63, 1372-1376.
32. Lewis, D. A.; Cho, R. Y.; Carter, C. S.; Eklund, K.; Forster, S.; Kelly, M. A.; Montrose, D. Subunit-selective modulation of GABAtype A receptor neurotransmission and cognition in schizophrenia, Am. J. Psychiatry, 2008, 165, 1585-1593.
33. Gaspar, P. A.; Bosman, C.; Ruiz, S.; Aboitiz, F. The Aberrant Connectivity Hypothesis in Schizophrenia. In: From Attention to Goal-Directed Behaviour: Neurodynamical, Methodological and Clinical Trends; Aboitiz, F., Cosmelli, D., Eds.; Springer-Verlag: Berlin, 2009.
34. Ford, J. M.; Roach, B. J.; Faustman, W. O.; Mathalon, D. H. Synch before you speak: auditory hallucinations in schizophrenia, Am. J. Psychiatry, 2007, 164, 458-466.
35. Spencer, K. M.; Nestor, P. G.; Niznikiewicz, M. A.; Salisbury, D. F.; Shenton, M. E.; McCarley, R. W. Abnormal neural synchrony in schizophrenia, J. Neurosci., 2003, 23, 7407-7411.
36. Toda, M.; Abi-Dargham, A. Dopamine hypothesis of schizophrenia: making sense of it all, Curr. Psychiatry Rep., 2007, 9, 329-336.
37. Howes, O. D.; Kapur, S. The dopamine hypothesis of schizophrenia: version III--the final common pathway, Schizophr. Bull., 2009, 35, 549-562.
38. Carlsson, A. Antipsychotic drugs, neurotransmitters, and schizophrenia, Am. J. Psychiatry, 1978, 135, 165-173.
39. Laruelle, M.; Frankle, W. G.; Narendran, R.; Kegeles, L. S.; Abi-Dargham, A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation, Clin. Ther., 2005, (27 Suppl. A), S16-24.
40. Stone, J. M.; Morrison, P. D.; Pilowsky, L. S. Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review, J. Psychopharmacol., 2007, 21, 440-452.
41. Shim, S. S.; Hammonds, M. D.; Kee, B. S. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site, Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258, 16-27.
42. Perea, G.; Navarrete, M.; Araque, A. Tripartite synapses: astrocytes process and control synaptic information, Trends. Neurosci., 2009, 32, 421-431.
43. Halassa, M. M.; Fellin, T.; Haydon, P. G. The tripartite synapse: roles for gliotransmission in health and disease, Trends. Mol. Med., 2007, 13, 54-63.
44. Araque, A.; Parpura, V.; Sanzgiri, R. P.; Haydon, P. G. Tripartite synapses: glia, the unacknowledged partner, Trends. Neurosci., 1999, 22, 208-215.
45. Perea, G.; Araque, A. GLIA modulates synaptic transmission, Brain. Res. Rev., 2010, 63(1/2), 93-102.
46. Hamilton, N. B.; Attwell, D. Do astrocytes really exocytose neurotransmitters?, Nat. Rev. Neurosci., 2010, 11, 227-238.
47. Mitterauer, B. J. Synaptic imbalances in endogenous psychoses, Biosystems, 2010, 100, 113-121.
48. Wieronska, J. M.; Pilc, A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs, Neurochem. Int., 2009, 55, 85-97.
49. Marcaggi, P.; Attwell, D. Role of glial amino acid transporters in synaptic transmission and brain energetics, Glia, 2004 47, 217-225.
50. Melone, M.; Vitellaro-Zuccarello, L.; Vallejo-Illarramendi, A.; Perez-Samartin, A.; Matute, C.; Cozzi, A.; Pellegrini-Giampietro, D. E.; Rothstein, J. D.; Conti, F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine, Mol. Psychiatry, 2001, 6, 380-386.
51. Wonodi, I.; Schwarcz, R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia, Schizophr. Bull., 2010, 36, 211-218.
52. Erhardt, S.; Olsson, S. K.; Engberg, G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders, CNS Drugs, 2009, 23, 91-101.
53. Gaspar, P. A.; Bustamante, M. L.; Silva, H.; Aboitiz, F. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications, J. Neurochem., 2009, 111, 891-900.
54. Dolman, N. P.; More, J. C.; Alt, A.; Knauss, J. L.; Pentikainen, O. T.; Glasser, C. R.; Bleakman, D.; Mayer, M. L.; Collingridge, G. L.; Jane, D. E. Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists, J. Med. Chem., 2007, 50, 1558-1570.
55. Dolman, N. P.; More, J. C.; Alt, A.; Knauss, J. L.; Troop, H. M.; Bleakman, D.; Collingridge, G. L.; Jane, D. E. Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists, J. Med. Chem., 2006, 49, 2579-2592.
56. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial, Nat. Med., 2007, 13, 1102-1107.
57. Chen, P. E.; Wyllie, D. J. Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors, Br. J. Pharmacol., 2006, 147, 839-853.
58. Butini, S.; Pickering, D. S.; Morelli, E.; Coccone, S. S.; Trotta, F.; De Angelis, M.; Guarino, E.; Fiorini, I.; Campiani, G.; Novellino, E.; Schousboe, A.; Christensen, J. K.; Gemma, S. 1Hcyclopentapyrimidine- 2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators, J. Med. Chem., 2008, 51, 6614-6618.
59. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien J. A.; Lemaire, W.; Williams, D. L. Jr.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5- yl)benzamides that potentiate receptor function in vivo, J. Med. Chem., 2004, 47, 5825-5828.
60. Spelman, L. M.; Walsh, P. I.; Sharifi, N.; Collins, P.; Thakore, J. H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia, Diabet. Med., 2007, 24, 481-485.
61. Bergman, R. N.; Ader, M. Atypical antipsychotics and glucose homeostasis, J. Clin. Psychiatry, 2005, 66, 504-514.
62. Verma, S. K.; Subramaniam, M.; Liew, A.; Poon, L. Y. Metabolic risk factors in drug-naive patients with first-episode psychosis, J. Clin. Psychiatry, 2009, 70, 997-1000.
63. McDermott, E.; de Silva, P. Impaired neuronal glucose uptake in pathogenesis of schizophrenia - can GLUT 1 and GLUT 3 deficits explain imaging, post-mortem and pharmacological findings?, Med. Hypotheses, 2005, 65, 1076-1081.
64. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Ahmadi Abhari, S. A.; Abbasi, S. H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial, Schizophr. Res., 2007, 90, 179-185.